Predict your next investment

Corporate Venture
venturefund.roche.com

See what CB Insights has to offer

Investments

133

Portfolio Exits

43

About Roche Venture Fund

The Roche Venture Fund is the name given to the corporate venture fund of the healthcare company Roche. Roche has allocated CHF 500 million for the Roche Venture Fund to invest in and develop commercially successful life science companies. The Roche Venture Fund is a committed long-term stable investor with sufficient money reserved for follow-on financing rounds. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally. The fund co-invests with leading venture funds, including other corporate venture funds, on a regular basis.

Roche Venture Fund Headquarter Location

Basel,

Switzerland

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Roche Venture Fund

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Roche Venture Fund in 1 CB Insights research brief, most recently on Jan 19, 2021.

Latest Roche Venture Fund News

GlycoEra AG appoints Ganesh V. Kaundinya as President and CEO

May 4, 2022

Ganesh V. Kaundinya Biotechnology company GlycoEra AG announced the appointment of Ganesh V. Kaundinya, Ph.D. as President and Chief Executive Officer. Dr. Kaundinya has been a member of the GlycoEra AG Board of Directors since the company’s inception in 2020, helping the team define corporate strategy and raise Series A capital of more than $49 million (CHF 45 million). Based on his deep industry expertise, Dr. Kaundinya will lead GlycoEra’s efforts to build a high-value pipeline of novel therapeutics using its proprietary glycoengineering platform, known as CustomGlycan. Under his leadership, the company will broaden its footprint by establishing a presence in Boston and continuing to grow its team in Zurich, the statement said. “I have been very impressed with the GlycoEra team’s accomplishments and am delighted to join them to build the next stage of the company,” said Dr. Kaundinya. “Glycans and glycan binding proteins play a critical role in human biology, including mediating cell-cell interactions, trafficking biomolecules for enhanced exposure or for degradation, and as receptors or co-receptors regulating immune cell biology. Our glycoengineering platform enables custom design and development of biologics that leverage these natural glycan receptors and pathways, with broad potential therapeutic applications across autoimmune diseases, oncology, neurology, allergy and infectious diseases.” Dr. Kaundinya brings extensive management, business development and scientific leadership experience to GlycoEra. Previously, he was Founder, Chief Operating Officer and Chief Scientific Officer of Momenta Pharmaceuticals, which was acquired by Johnson & Johnson for $6.5 billion in 2020. Under his guidance, Momenta developed a portfolio of complex generics, biosimilars and novel biologic products that included carbohydrates, complex peptides, glycoproteins, antibodies and Fc fusion proteins, for therapeutic indications in cardiovascular, autoimmune diseases and oncology. Dr. Kaundinya led the teams that discovered and developed multiple products at Momenta for launch in collaboration with Sandoz Pharmaceuticals (Novartis), and forged high-value alliances with Sandoz, Baxter/Baxalta (now Shire), Mylan and CSL. “We are delighted with the appointment of Dr. Kaundinya to the role of President and CEO because he brings critical experience in biopharmaceutical company building and operation to GlycoEra just as the company establishes itself in Boston and continues to grow its research team in Zurich,” said Graziano Seghezzi, Managing Partner at Sofinnova Partners and a member of GlycoEra’s Board of Directors. “We are very excited about the potential of the CustomGlycan platform to enable understanding of glycan roles in biology and develop therapeutic products,” said Monique Schiersing, Senior Investment Director at Roche Venture Fund and a member of GlycoEra’s Board of Directors. “Dr. Kaundinya brings the perfect combination of business and scientific leadership to guide GlycoEra through the process of building the right team to translate this powerful glycoengineering platform into a high-value pipeline of product candidates.” Prior to founding Momenta, Dr. Kaundinya was Director, Bioinformatics Consortium for Glycomics, at Massachusetts Institute of Technology (MIT), and was part of the research faculty at MIT, where he led a team of researchers, along with Dr. Robert Langer, to study and invent novel sequencing technology for complex sugars. Dr. Kaundinya joins a leadership team comprised of seasoned biotechnology executives, including Amir Faridmoayer, Ph.D., Chief Technology Officer, and Dominique Sirena, Ph.D., Chief Manufacturing Officer. He succeeds Veronica Gambillara Fonck, Ph.D., a GlycoEra co-founder who served as CEO since the company’s inception. GlycoEra is backed by an international investor syndicate of renowned US and European life science investors including 5AM Ventures, Sofinnova Partners, and Roche Venture Fund, which co-led a $49 million (CHF 45 million) Series A financing round in October 2021. Ashish Nain

Roche Venture Fund Investments

133 Investments

Roche Venture Fund has made 133 investments. Their latest investment was in NMD Pharma as part of their Unattributed VC on February 2, 2022.

CBI Logo

Roche Venture Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/15/2022

Unattributed VC

NMD Pharma

$39.72M

No

3

1/11/2022

Series E

Freenome

$290M

No

12

12/22/2021

Series B

Bonum Therapeutics

$1.19M

Yes

1

12/22/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/5/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/15/2022

1/11/2022

12/22/2021

12/22/2021

11/5/2021

Round

Unattributed VC

Series E

Series B

Series B

Series A

Company

NMD Pharma

Freenome

Bonum Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$39.72M

$290M

$1.19M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

12

1

10

10

Roche Venture Fund Portfolio Exits

43 Portfolio Exits

Roche Venture Fund has 43 portfolio exits. Their latest portfolio exit was Entrada Therapeutics on October 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/29/2021

IPO

$99M

7

9/24/2021

Reverse Merger

3

4/1/2021

Acquired

3

10/16/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

10/2/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/29/2021

9/24/2021

4/1/2021

10/16/2020

10/2/2020

Exit

IPO

Reverse Merger

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

3

3

10

10

Roche Venture Fund Acquisitions

1 Acquisition

Roche Venture Fund acquired 1 company. Their latest acquisition was Cardion on July 22, 2003.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/22/2003

Series C

$99M

$55.19M

Asset Sale

1

Date

7/22/2003

Investment Stage

Series C

Companies

Valuation

$99M

Total Funding

$55.19M

Note

Asset Sale

Sources

1

Roche Venture Fund Team

4 Team Members

Roche Venture Fund has 4 team members, including former President, Patrick J Zenner.

Name

Work History

Title

Status

Patrick J Zenner

President

Former

Erich Hunziker

Chief Financial Officer

Former

Pearl Huang

Senior Vice President

Former

Rob Mitchell

Managing Director

Former

Name

Patrick J Zenner

Erich Hunziker

Pearl Huang

Rob Mitchell

Work History

Title

President

Chief Financial Officer

Senior Vice President

Managing Director

Status

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.